Michal Ayalon
Keine laufenden Positionen mehr
Profil
Michal Ayalon worked as Vice President of Research and Development at Kamada Ltd.
from 2019 to 2022.
Prior to that, she held the same position at Galmed Pharmaceuticals Ltd.
in 2015-2016.
In 2018-2019, she was Head of Research and Development at 89Bio Ltd.
Ayalon received her undergraduate, graduate, and doctorate degrees from Tel-Aviv University.
Ehemalige bekannte Positionen von Michal Ayalon
| Unternehmen | Position | Ende |
|---|---|---|
| KAMADA LTD. | Technik-/Wissenschafts-/F&E-Leiter | 28.02.2022 |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
| GALMED PHARMACEUTICALS LTD. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2016 |
Ausbildung von Michal Ayalon
| Tel-Aviv University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GALMED PHARMACEUTICALS LTD. | Health Technology |
| KAMADA LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Health Technology |
